Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances
Author:
- 24 April 2019
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 42 (8) , 973-992
Abstract
Cutaneous adverse drug reactions are unpredictable and include various different skin conditions of varying degrees of severity. The most concerning are usually referred to as severe cutaneous adverse reactions (SCARs) and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DiHS) or hypersensitivity syndrome (HSS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). All are delayed type IV hypersensitivity reactions in which a T-cell-mediated drug-specific immune response is responsible for causing the disease. Nonetheless, specific T-cell subpopulations develop in response to certain environmental conditions and produce cytokines that orchestrate the various phenotypes. Cytotoxic T lymphocytes (CTLs), T-helper type 1 (Th1), Th2, Th17, and regulatory T cells (Treg), among other T-cell subpopulations, participate in the development of SCAR phenotypes. Cell subpopulations belonging to the innate immune system, comprising natural killer cells, innate lymphoid cells, monocytes, macrophages and dendritic cells, can also participate in shaping specific immune responses in various clinical conditions. Additionally, tissue-resident cells, including keratinocytes, can contribute to epidermal damage by secreting chemokines that attract pro-inflammatory immunocytes. The final phenotypes in each clinical entity result from the complex interactions between a variety of cell lineages, their products, soluble mediators and genetic and environmental factors. Although the pathophysiology of these reactions is not fully understood, intensive research in recent years has led to major progress in our understanding of the contribution of certain cell types and soluble mediators to the variability of SCAR phenotypes.Keywords
Funding Information
- Instituto de Salud Carlos III (FIS PI13/01768)
This publication has 199 references indexed in Scilit:
- Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 casesBritish Journal of Dermatology, 2013
- Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoireProceedings of the National Academy of Sciences, 2012
- A quarter century of granzymesCell Death & Differentiation, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- DAMPening Inflammation by Modulating TLR SignallingMediators of Inflammation, 2010
- “Danger” Conditions Increase Sulfamethoxazole-Protein Adduct Formation in Human Antigen-Presenting CellsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Membrane-bound Fas ligand only is essential for Fas-induced apoptosisNature, 2009
- A Complex Interaction Between Drug Allergy and Viral InfectionClinical Reviews in Allergy & Immunology, 2007
- Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics, 2006
- Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.Journal of Clinical Investigation, 1988